Editas Medicine, Inc. SEC filings EDIT
Editas Medicine, Inc. has 727 filings in SEC EDGAR's recent list, going back to Aug 18, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Apr 28, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| DEFA14A | Additional proxy material | Apr 15, 2025 | — |
| DEF 14A | Proxy statement | Apr 15, 2025 | Apr 15, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2025 | Apr 4, 2025 |
| DEFA14A | Additional proxy material | Apr 16, 2024 | — |
| DEF 14A | Proxy statement | Apr 16, 2024 | Apr 16, 2024 |
| DEFA14A | Additional proxy material | Apr 18, 2023 | — |
| DEF 14A | Proxy statement | Apr 18, 2023 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 9, 2022 |
| DEFA14A | Additional proxy material | May 21, 2021 | — |
| DEFA14A | Additional proxy material | Apr 20, 2021 | — |
| DEF 14A | Proxy statement | Apr 20, 2021 | Jun 3, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 10, 2020 |
| DEFA14A | Additional proxy material | Apr 26, 2019 | — |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 12, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 15, 2018 |
| DEFA14A | Additional proxy material | May 31, 2017 | — |
| DEFA14A | Additional proxy material | Apr 26, 2017 | — |
| DEF 14A | Proxy statement | Apr 26, 2017 | Jun 15, 2017 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EDIT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1650664
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.